美国联合医疗保健公司现在为5100万美国人提供Plus Therapeutics脑液瘤检测, UnitedHealthcare now covers Plus Therapeutics’ CSF tumor test for 51 million Americans, boosting access to a highly accurate test for brain cancer monitoring.

普拉斯治疗公司的子公司 CNSide Diagnostics 与 UnitedHealthcare 签订了一项全国性覆盖协议,该协议自 2025 年 9 月 15 日起生效,为超过 5100 万美国人提供其研发的脑脊髓瘤细胞计数实验室测试. Plus Therapeutics' subsidiary CNSide Diagnostics has secured a national coverage agreement with UnitedHealthcare, effective September 15, 2025, granting access to its CSF Tumor Cell Enumeration laboratory-developed test for over 51 million Americans. 该测试用于诊断和监测淋巴乳腺转移,显示出92%的敏感性和95%的特殊性,对90%的病例的治疗决定产生了影响,其依据是自2020年以来在120多个美国癌症中心进行的超过11 000次测试的数据。 The test, used for diagnosing and monitoring leptomeningeal metastases, has shown 92% sensitivity and 95% specificity, influencing treatment decisions in 90% of cases based on data from over 11,000 tests at more than 120 U.S. cancer centers since 2020. 在9项经同行审查的研究和FORESEE试验的支持下,该试验能够对肿瘤细胞进行定量分析,并传播DNA。 Supported by nine peer-reviewed studies and the FORESEE trial, the test enables quantitative analysis of tumor cells and circulating DNA. 休斯顿的实验室获得了CMS认证, 普拉斯治疗公司从CPRIT获得了190万美元的预付款, The Houston-based lab earned CMS accreditation, and Plus Therapeutics received a $1.9 million advance from CPRIT as part of a $17.6 million grant. 尽管有这些发展,该公司的股票在市场前贸易中以0.39美元关闭。 Despite these developments, the company’s stock closed at $0.39 in premarket trading.